English
French
Equine Allogeneic Chondrogenic Induced Mesenchymal Stem Cells Are an Effective Treatment for Degenerative Joint Disease in Horses.
Abstract: Degenerative joint disease is one of the main causes of equine early retirement from pleasure riding or a performance career. The disease is initially triggered by an abnormal loading of normal cartilage or a normal loading of abnormal cartilage. This primary insult is accompanied with joint inflammation, which leads to further progressive degeneration of the articular cartilage and changes in the surrounding tissues. Therefore, in search for an effective treatment, 75 adult horses with early signs of degenerative fetlock joint disease were enrolled in a randomized, multicenter, double-blinded, and placebo-controlled study. Fifty animals were injected intra-articularly with the investigational veterinary product (IVP) consisting of allogeneic chondrogenic induced mesenchymal stem cells (ciMSCs) with equine allogeneic plasma, and 25 horses were injected with 0.9% NaCl (saline) control product. From week 3 to 18 after treatment, lameness scores (P < 0.001), flexion test responses (P < 0.034), and joint effusion scores (P < 0.001) were remarkably superior in IVP-treated horses. Besides nasal discharge in both treatment groups, no adverse events were observed during the entire study period. On long-term follow-up (1 year), significantly more investigational product-treated horses were working at training level or were returned to their previous level of work (P < 0.001).
Publication Date: 2019-02-13 PubMed ID: 30623737PubMed Central: PMC6441287DOI: 10.1089/scd.2018.0061Google Scholar: Lookup The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Veterinary
- Research Support
- Non-U.S. Gov't
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The research article investigates how a treatment involving the injection of stem cells can help in treating early signs of Degenerative Joint Disease (DJD) in horses. The study results demonstrate a significant improvement in the condition of horses treated with this method when compared to a control group.
Research Context and Aim
- Degenerative Joint Disease (DJD) is a significant cause for early retirement in horses, often affecting their performance and pleasure riding abilities. This disease is primarily triggered by abnormal or extreme stress exerted on the cartilage.
- Given the need for effective treatments, the researchers conducted a randomized, multicenter, double-blinded, and placebo-controlled study involving 75 adult horses showing early signs of DJD.
Research Method
- Of the total of 75 horses, 50 were treated with an injection of allogeneic chondrogenic induced mesenchymal stem cells (ciMSCs) combined with equine allogeneic plasma. This experimental veterinary product aimed to regenerate damaged cartilage, improving the condition of the joint. This experimental group is referred to as the “IVP-treated horses” in the study.
- The remaining 25 horses were injected with a saline solution as a control group.
- Several aspects such as lameness scores, flexion test responses, and joint effusion scores were recorded and analysed from week 3 to week 18 after the treatment.
Research Findings
- Compared to the control group, IVP-treated horses showed significant improvement in the aforementioned aspects. For instance, scores for lameness, flexion test responses, and joint effusion were notably better in IVP-treated horses.
- The study noted no adverse events in both groups, except for nasal discharge. This indicates that the treatment was well-tolerated by the animals.
- In a longer-term follow-up (1 year), substantially more horses treated with the stem cell product were able to return to their prior level of work or were working at training level. Thus, the treatment was not only effective in the short-term but also in the long run.
Conclusions
- The findings suggest that the use of mesenchymal stem cells can be an effective strategy for treating DJD in horses.
- However, further research may be required to explore the full potential of this treatment strategy, understand its effects in greater detail, and investigate potential risks or side effects associated with repeated or long-term use.
Cite This Article
APA
Broeckx SY, Seys B, Suls M, Vandenberghe A, Mariu00ebn T, Adriaensen E, Declercq J, Van Hecke L, Braun G, Hellmann K, Spaas JH.
(2019).
Equine Allogeneic Chondrogenic Induced Mesenchymal Stem Cells Are an Effective Treatment for Degenerative Joint Disease in Horses.
Stem Cells Dev, 28(6), 410-422.
https://doi.org/10.1089/scd.2018.0061 Publication
Researcher Affiliations
- 1 Global Stem cell Technology NV, Anacura Group, Evergem, Belgium.
- 2 Equine Veterinary Practice Dr Suls, SP Weert, the Netherlands.
- 2 Equine Veterinary Practice Dr Suls, SP Weert, the Netherlands.
- 3 Equine Veterinary Service Adriaensen-Vandenberghe, Waasmunster, Belgium.
- 4 Equitom Equine Hospital, Meldert, Belgium.
- 3 Equine Veterinary Service Adriaensen-Vandenberghe, Waasmunster, Belgium.
- 4 Equitom Equine Hospital, Meldert, Belgium.
- 5 Veterinary Practitioner, Oudenaarde, Belgium.
- 1 Global Stem cell Technology NV, Anacura Group, Evergem, Belgium.
- 6 Klifovet AG, Munich, Germany.
- 6 Klifovet AG, Munich, Germany.
- 1 Global Stem cell Technology NV, Anacura Group, Evergem, Belgium.
MeSH Terms
- Allografts
- Animals
- Double-Blind Method
- Female
- Follow-Up Studies
- Horse Diseases / pathology
- Horse Diseases / therapy
- Horses
- Injections, Intra-Articular
- Joint Diseases / pathology
- Joint Diseases / therapy
- Joint Diseases / veterinary
- Male
- Mesenchymal Stem Cell Transplantation
- Mesenchymal Stem Cells
Conflict of Interest Statement
The author J.H.S. declares competing financial interests as shareholder in Global Stem cell Technology (GST) NV. S.Y.B., J.H.S., and L.V.H. are all employed by GST. S.Y.B. and J.H.S. are inventors of several pending patents owned by GST (BE2012/0656; WO2014053418A9; WO2014053420A1; PCT/EP2013/075782). G.B. and K.H. are employees of KLIFOVET AG, who was compensated by GST for regulatory consultancy and monitoring of the study. The statistical analysis was performed by an independent statistician employed by KLIFOVET AG. All other authors declare no conflict of interests. The content of this article contains the product Arti-Cell Forte owned by GST.
References
This article includes 59 references
- McIlwraith CW, Frisbie DD, Kawcak CE. The horse as a model of naturally occurring osteoarthritis.. Bone Joint Res 2012 Nov;1(11):297-309.
- McIlwraith CW. (2005). From Arthroscopy to gene therapyu201430 years of looking into joints. In: Annual Convention of the AAEP, 3u20137 December, Seattle, IVIS: Washington, USA
- Sutton S, Clutterbuck A, Harris P, Gent T, Freeman S, Foster N, Barrett-Jolley R, Mobasheri A. The contribution of the synovium, synovial derived inflammatory cytokines and neuropeptides to the pathogenesis of osteoarthritis.. Vet J 2009 Jan;179(1):10-24.
- Neundorf RH, Lowerison MB, Cruz AM, Thomason JJ, McEwen BJ, Hurtig MB. Determination of the prevalence and severity of metacarpophalangeal joint osteoarthritis in Thoroughbred racehorses via quantitative macroscopic evaluation.. Am J Vet Res 2010 Nov;71(11):1284-93.
- van Weeren PR, de Grauw JC. Pain in osteoarthritis.. Vet Clin North Am Equine Pract 2010 Dec;26(3):619-42.
- Liljenstolpe C. (2009). Horses in Europe. Equus Conference 1:2u20133
- nAmerican Hourse Council. (2017). Economic Impact of the United States Horse Industry. www.horsecouncil.org/resources/economics/ accessed February4,n2019
- Malone ED. Managing chronic arthritis.. Vet Clin North Am Equine Pract 2002 Dec;18(3):411-37.
- Nizolek DJ, White KK. Corticosteroid and hyaluronic acid treatments in equine degenerative joint disease. A review.. Cornell Vet 1981 Oct;71(4):355-75.
- Goodrich LR, Nixon AJ. Medical treatment of osteoarthritis in the horse - a review.. Vet J 2006 Jan;171(1):51-69.
- Contino EK. Management and Rehabilitation of Joint Disease in Sport Horses.. Vet Clin North Am Equine Pract 2018 Aug;34(2):345-358.
- de Grauw JC, Visser-Meijer MC, Lashley F, Meeus P, van Weeren PR. Intra-articular treatment with triamcinolone compared with triamcinolone with hyaluronate: A randomised open-label multicentre clinical trial in 80 lame horses.. Equine Vet J 2016 Mar;48(2):152-8.
- Oke SL. and McIlwraith CW. (2010). Review of the economic impact of osteoarthritis and oral joint-health supplements in horses. In: Annual Convention of the AAEP, 4u20138 December, Baltimore, IVIS: Maryland, USA
- Wilke MM, Nydam DV, Nixon AJ. Enhanced early chondrogenesis in articular defects following arthroscopic mesenchymal stem cell implantation in an equine model.. J Orthop Res 2007 Jul;25(7):913-25.
- Frisbie DD, Kisiday JD, Kawcak CE, Werpy NM, McIlwraith CW. Evaluation of adipose-derived stromal vascular fraction or bone marrow-derived mesenchymal stem cells for treatment of osteoarthritis.. J Orthop Res 2009 Dec;27(12):1675-80.
- McIlwraith CW, Frisbie DD, Rodkey WG, Kisiday JD, Werpy NM, Kawcak CE, Steadman JR. Evaluation of intra-articular mesenchymal stem cells to augment healing of microfractured chondral defects.. Arthroscopy 2011 Nov;27(11):1552-61.
- Broeckx S, Zimmerman M, Crocetti S, Suls M, Mariu00ebn T, Ferguson SJ, Chiers K, Duchateau L, Franco-Obregu00f3n A, Wuertz K, Spaas JH. Regenerative therapies for equine degenerative joint disease: a preliminary study.. PLoS One 2014;9(1):e85917.
- Berg L, Koch T, Heerkens T, Bessonov K, Thomsen P, Betts D. Chondrogenic potential of mesenchymal stromal cells derived from equine bone marrow and umbilical cord blood.. Vet Comp Orthop Traumatol 2009;22(5):363-70.
- Spaas JH, Broeckx SY, Chiers K, Ferguson SJ, Casarosa M, Van Bruaene N, Forsyth R, Duchateau L, Franco-Obregu00f3n A, Wuertz-Kozak K. Chondrogenic Priming at Reduced Cell Density Enhances Cartilage Adhesion of Equine Allogeneic MSCs - a Loading Sensitive Phenomenon in an Organ Culture Study with 180 Explants.. Cell Physiol Biochem 2015;37(2):651-65.
- Spaas JH, De Schauwer C, Cornillie P, Meyer E, Van Soom A, Van de Walle GR. Culture and characterisation of equine peripheral blood mesenchymal stromal cells.. Vet J 2013 Jan;195(1):107-13.
- Spees JL, Lee RH, Gregory CA. Mechanisms of mesenchymal stem/stromal cell function.. Stem Cell Res Ther 2016 Aug 31;7(1):125.
- Meirelles Lda S, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells.. Cytokine Growth Factor Rev 2009 Oct-Dec;20(5-6):419-27.
- Broeckx S, Suls M, Beerts C, Vandenberghe A, Seys B, Wuertz-Kozak K, Duchateau L, Spaas JH. Allogenic mesenchymal stem cells as a treatment for equine degenerative joint disease: a pilot study.. Curr Stem Cell Res Ther 2014;9(6):497-503.
- Ferris DJ, Frisbie DD, Kisiday JD, McIlwraith CW, Hague BA, Major MD, Schneider RK, Zubrod CJ, Kawcak CE, Goodrich LR. Clinical outcome after intra-articular administration of bone marrow derived mesenchymal stem cells in 33 horses with stifle injury.. Vet Surg 2014 Mar;43(3):255-65.
- Faltus T, Brehm W. Cell-Based Veterinary Pharmaceuticals - Basic Legal Parameters Set by the Veterinary Pharmaceutical Law and the Genetic Engineering Law of the European Union.. Front Vet Sci 2016;3:101.
- Fung M, Yuan Y, Atkins H, Shi Q, Bubela T. Responsible Translation of Stem Cell Research: An Assessment of Clinical Trial Registration and Publications.. Stem Cell Reports 2017 May 9;8(5):1190-1201.
- Vu00e9zina Audette R, Lavoie-Lamoureux A, Lavoie JP, Laverty S. Inflammatory stimuli differentially modulate the transcription of paracrine signaling molecules of equine bone marrow multipotent mesenchymal stromal cells.. Osteoarthritis Cartilage 2013 Aug;21(8):1116-24.
- Broeckx S, Zimmerman M, Aerts D, Seys B, Suls M, Mariu00ebn T. and Spaas JH. (2012). Tenogenesis of equine peripheral blood-derived mesenchymal stem cells: in vitro versus in vivo. J Tissue Sci Eng S11u2013001:1u20136
- Beerts C, Seifert C, Zimmerman M, Felix E, Suls M, Mariu00ebn T, Broeckx S. and Spaas JH. (2013). Desmitis of the accessory ligament of the equine deep digital flexor tendon: a regenerative approach. J Tissue Sci Eng 03:125
- Broeckx S, de Vries C, Suls M, Guest DJ. and Spaas JH. (2013). Guidelines to optimize survival and migration capacities of equine mesenchymal stem cells. J Stem Cell Res Ther 3:147
- Saltzman BM, Leroux T, Meyer MA, Basques BA, Chahal J, Bach BR Jr, Yanke AB, Cole BJ. The Therapeutic Effect of Intra-articular Normal Saline Injections for Knee Osteoarthritis: A Meta-analysis of Evidence Level 1 Studies.. Am J Sports Med 2017 Sep;45(11):2647-2653.
- Mishra A, Tummala P, King A, Lee B, Kraus M, Tse V, Jacobs CR. Buffered platelet-rich plasma enhances mesenchymal stem cell proliferation and chondrogenic differentiation.. Tissue Eng Part C Methods 2009 Sep;15(3):431-5.
- Colbath AC, Dow SW, Phillips JN, McIlwraith CW, Goodrich LR. Autologous and Allogeneic Equine Mesenchymal Stem Cells Exhibit Equivalent Immunomodulatory Properties In Vitro.. Stem Cells Dev 2017 Apr 1;26(7):503-511.
- Paterson YZ, Rash N, Garvican ER, Paillot R, Guest DJ. Equine mesenchymal stromal cells and embryo-derived stem cells are immune privileged in vitro.. Stem Cell Res Ther 2014 Jul 30;5(4):90.
- Carrade DD, Lame MW, Kent MS, Clark KC, Walker NJ, Borjesson DL. Comparative Analysis of the Immunomodulatory Properties of Equine Adult-Derived Mesenchymal Stem Cells().. Cell Med 2012;4(1):1-11.
- Pigott JH, Ishihara A, Wellman ML, Russell DS, Bertone AL. Investigation of the immune response to autologous, allogeneic, and xenogeneic mesenchymal stem cells after intra-articular injection in horses.. Vet Immunol Immunopathol 2013 Nov 15;156(1-2):99-106.
- Joswig AJ, Mitchell A, Cummings KJ, Levine GJ, Gregory CA, Smith R 3rd, Watts AE. Repeated intra-articular injection of allogeneic mesenchymal stem cells causes an adverse response compared to autologous cells in the equine model.. Stem Cell Res Ther 2017 Feb 28;8(1):42.
- Caron JP. (2011). Osteoarthritis. In: Diagnosis and Management of Lameness in the Horse, 2nd ed. ed Ross MW, Dyson SJ, eds. Elsevier Saunders, St. Louis, MO, pp. 655u2013668
- Ardanaz N, Vu00e1zquez FJ, Romero A, Remacha AR, Barrachina L, Sanz A, Ranera B, Vitoria A, Albareda J, Prades M, Zaragoza P, Martu00edn-Burriel I, Rodellar C. Inflammatory response to the administration of mesenchymal stem cells in an equine experimental model: effect of autologous, and single and repeat doses of pooled allogeneic cells in healthy joints.. BMC Vet Res 2016 Mar 31;12:65.
- Schnabel LV, Pezzanite LM, Antczak DF, Felippe MJ, Fortier LA. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro.. Stem Cell Res Ther 2014 Jan 24;5(1):13.
- Hill JA, Cassano JM, Goodale MB, Fortier LA. Antigenicity of mesenchymal stem cells in an inflamed joint environment.. Am J Vet Res 2017 Jul;78(7):867-875.
- Berglund AK, Fisher MB, Cameron KA, Poole EJ, Schnabel LV. Transforming Growth Factor-u03b22 Downregulates Major Histocompatibility Complex (MHC) I and MHC II Surface Expression on Equine Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Other Phenotypic Cell Surface Markers.. Front Vet Sci 2017;4:84.
- Pezzanite LM, Fortier LA, Antczak DF, Cassano JM, Brosnahan MM, Miller D, Schnabel LV. Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo.. Stem Cell Res Ther 2015 Apr 12;6(1):54.
- Carrade DD, Owens SD, Galuppo LD, Vidal MA, Ferraro GL, Librach F, Buerchler S, Friedman MS, Walker NJ, Borjesson DL. Clinicopathologic findings following intra-articular injection of autologous and allogeneic placentally derived equine mesenchymal stem cells in horses.. Cytotherapy 2011 Apr;13(4):419-30.
- Park SA, Reilly CM, Wood JA, Chung DJ, Carrade DD, Deremer SL, Seraphin RL, Clark KC, Zwingenberger AL, Borjesson DL, Hayashi K, Russell P, Murphy CJ. Safety and immunomodulatory effects of allogeneic canine adipose-derived mesenchymal stromal cells transplanted into the region of the lacrimal gland, the gland of the third eyelid and the knee joint.. Cytotherapy 2013 Dec;15(12):1498-510.
- Richardson JD, Bertaso AG, Psaltis PJ, Frost L, Carbone A, Paton S, Nelson AJ, Wong DT, Worthley MI, Gronthos S, Zannettino AC, Worthley SG. Impact of timing and dose of mesenchymal stromal cell therapy in a preclinical model of acute myocardial infarction.. J Card Fail 2013 May;19(5):342-53.
- Joo SY, Cho KA, Jung YJ, Kim HS, Park SY, Choi YB, Hong KM, Woo SY, Seoh JY, Cho SJ, Ryu KH. Mesenchymal stromal cells inhibit graft-versus-host disease of mice in a dose-dependent manner.. Cytotherapy 2010 May;12(3):361-70.
- Saether EE, Chamberlain CS, Leiferman EM, Kondratko-Mittnacht JR, Li WJ, Brickson SL, Vanderby R. Enhanced medial collateral ligament healing using mesenchymal stem cells: dosage effects on cellular response and cytokine profile.. Stem Cell Rev Rep 2014 Feb;10(1):86-96.
- Vangsness CT Jr, Farr J 2nd, Boyd J, Dellaero DT, Mills CR, LeRoux-Williams M. Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy: a randomized, double-blind, controlled study.. J Bone Joint Surg Am 2014 Jan 15;96(2):90-8.
- Quimby JM, Webb TL, Habenicht LM, Dow SW. Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies.. Stem Cell Res Ther 2013 Apr 30;4(2):48.
- Quimby JM, Webb TL, Randall E, Marolf A, Valdes-Martinez A, Dow SW. Assessment of intravenous adipose-derived allogeneic mesenchymal stem cells for the treatment of feline chronic kidney disease: a randomized, placebo-controlled clinical trial in eight cats.. J Feline Med Surg 2016 Feb;18(2):165-71.
- Sellon DC, Levine J, Millikin E, Palmer K, Grindem C, Covington P. Thrombocytopenia in horses: 35 cases (1989-1994).. J Vet Intern Med 1996 May-Jun;10(3):127-32.
- Moraes AP, Moreira JJ, Brossi PM, Machado TS, Michelacci YM, Baccarin RY. Short- and long-term effects of platelet-rich plasma upon healthy equine joints: Clinical and laboratory aspects.. Can Vet J 2015 Aug;56(8):831-8.
- Keegan KG, Wilson DA, Kramer J, Reed SK, Yonezawa Y, Maki H, Pai PF, Lopes MA. Comparison of a body-mounted inertial sensor system-based method with subjective evaluation for detection of lameness in horses.. Am J Vet Res 2013 Jan;74(1):17-24.
- Keegan KG. Evidence-based lameness detection and quantification.. Vet Clin North Am Equine Pract 2007 Aug;23(2):403-23.
- Keegan KG, Kramer J, Yonezawa Y, Maki H, Pai PF, Dent EV, Kellerman TE, Wilson DA, Reed SK. Assessment of repeatability of a wireless, inertial sensor-based lameness evaluation system for horses.. Am J Vet Res 2011 Sep;72(9):1156-63.
- Fuller CJ, Bladon BM, Driver AJ, Barr AR. The intra- and inter-assessor reliability of measurement of functional outcome by lameness scoring in horses.. Vet J 2006 Mar;171(2):281-6.
- Hewetson M, Christley RM, Hunt ID, Voute LC. Investigations of the reliability of observational gait analysis for the assessment of lameness in horses.. Vet Rec 2006 Jun 24;158(25):852-7.
- Keegan KG, Dent EV, Wilson DA, Janicek J, Kramer J, Lacarrubba A, Walsh DM, Cassells MW, Esther TM, Schiltz P, Frees KE, Wilhite CL, Clark JM, Pollitt CC, Shaw R, Norris T. Repeatability of subjective evaluation of lameness in horses.. Equine Vet J 2010 Mar;42(2):92-7.
Citations
This article has been cited 20 times.- Leal Reis I, Lopes B, Sousa P, Sousa AC, Branquinho M, Caseiro AR, Pedrosa SS, Ru00eama A, Oliveira C, Porto B, Atayde L, Amorim I, Alvites R, Santos JM, Mauru00edcio AC. Allogenic Synovia-Derived Mesenchymal Stem Cells for Treatment of Equine Tendinopathies and Desmopathies-Proof of Concept.. Animals (Basel) 2023 Apr 11;13(8).
- Mayet A, Zablotski Y, Roth SP, Brehm W, Troillet A. Systematic review and meta-analysis of positive long-term effects after intra-articular administration of orthobiologic therapeutics in horses with naturally occurring osteoarthritis.. Front Vet Sci 2023;10:1125695.
- Liu L, Qiu L, Zhu Y, Luo L, Han X, Man M, Li F, Ren M, Xing Y. Comparisons between Plant and Animal Stem Cells Regarding Regeneration Potential and Application.. Int J Mol Sci 2023 Feb 23;24(5).
- Zhu Y, Fu W. Peripheral Blood-Derived Stem Cells for the Treatment of Cartilage Injuries: A Systematic Review.. Front Bioeng Biotechnol 2022;10:956614.
- Kearney CM, Khatab S, van Buul GM, Plomp SGM, Korthagen NM, Labbertu00e9 MC, Goodrich LR, Kisiday JD, Van Weeren PR, van Osch GJVM, Brama PAJ. Treatment Effects of Intra-Articular Allogenic Mesenchymal Stem Cell Secretome in an Equine Model of Joint Inflammation.. Front Vet Sci 2022;9:907616.
- Roth SP, Burk J, Brehm W, Troillet A. MSC in Tendon and Joint Disease: The Context-Sensitive Link Between Targets and Therapeutic Mechanisms.. Front Bioeng Biotechnol 2022;10:855095.
- Hagen A, Holland H, Brandt VP, Doll CU, Hu00e4uu00dfler TC, Melzer M, Moellerberndt J, Lehmann H, Burk J. Platelet Lysate for Mesenchymal Stromal Cell Culture in the Canine and Equine Species: Analogous but Not the Same.. Animals (Basel) 2022 Jan 13;12(2).
- Mund SJK, MacPhee DJ, Campbell J, Honaramooz A, Wobeser B, Barber SM. Macroscopic, Histologic, and Immunomodulatory Response of Limb Wounds Following Intravenous Allogeneic Cord Blood-Derived Multipotent Mesenchymal Stromal Cell Therapy in Horses.. Cells 2021 Nov 1;10(11).
- Hotham WE, Thompson C, Szu-Ting L, Henson FMD. The anti-inflammatory effects of equine bone marrow stem cell-derived extracellular vesicles on autologous chondrocytes.. Vet Rec Open 2021 Dec;8(1):e22.
- Przu0105dka P, Buczak K, Frejlich E, Gu0105sior L, Suliga K, Kieu0142bowicz Z. The Role of Mesenchymal Stem Cells (MSCs) in Veterinary Medicine and Their Use in Musculoskeletal Disorders.. Biomolecules 2021 Aug 2;11(8).
- Zayed M, Adair S, Dhar M. Effects of Normal Synovial Fluid and Interferon Gamma on Chondrogenic Capability and Immunomodulatory Potential Respectively on Equine Mesenchymal Stem Cells.. Int J Mol Sci 2021 Jun 15;22(12).
- Ganiev I, Alexandrova N, Aimaletdinov A, Rutland C, Malanyeva A, Rizvanov A, Zakirova E. The treatment of articular cartilage injuries with mesenchymal stem cells in different animal species.. Open Vet J 2021 Jan-Mar;11(1):128-134.
- Bertoni L, Jacquet-Guibon S, Branly T, Desancu00e9 M, Legendre F, Melin M, Rivory P, Hartmann DJ, Schmutz A, Denoix JM, Demoor M, Audigiu00e9 F, Galu00e9ra P. Evaluation of Allogeneic Bone-Marrow-Derived and Umbilical Cord Blood-Derived Mesenchymal Stem Cells to Prevent the Development of Osteoarthritis in An Equine Model.. Int J Mol Sci 2021 Mar 2;22(5).
- Hagen A, Lehmann H, Aurich S, Bauer N, Melzer M, Moellerberndt J, Patanu00e9 V, Schnabel CL, Burk J. Scalable Production of Equine Platelet Lysate for Multipotent Mesenchymal Stromal Cell Culture.. Front Bioeng Biotechnol 2020;8:613621.
- Kamm JL, Riley CB, Parlane N, Gee EK, McIlwraith CW. Interactions Between Allogeneic Mesenchymal Stromal Cells and the Recipient Immune System: A Comparative Review With Relevance to Equine Outcomes.. Front Vet Sci 2020;7:617647.
- Kim KH, Park TS, Cho BW, Kim TM. Nanoparticles from Equine Fetal Bone Marrow-Derived Cells Enhance the Survival of Injured Chondrocytes.. Animals (Basel) 2020 Sep 23;10(10).
- Mocchi M, Dotti S, Bue MD, Villa R, Bari E, Perteghella S, Torre ML, Grolli S. Veterinary Regenerative Medicine for Musculoskeletal Disorders: Can Mesenchymal Stem/Stromal Cells and Their Secretome Be the New Frontier?. Cells 2020 Jun 11;9(6).
- Chen YR, Yan X, Yuan FZ, Ye J, Xu BB, Zhou ZX, Mao ZM, Guan J, Song YF, Sun ZW, Wang XJ, Chen ZY, Wang DY, Fan BS, Yang M, Song ST, Jiang D, Yu JK. The Use of Peripheral Blood-Derived Stem Cells for Cartilage Repair and Regeneration In Vivo: A Review.. Front Pharmacol 2020;11:404.
- Magri C, Schramme M, Febre M, Cauvin E, Labadie F, Saulnier N, Franu00e7ois I, Lechartier A, Aebischer D, Moncelet AS, Maddens S. Comparison of efficacy and safety of single versus repeated intra-articular injection of allogeneic neonatal mesenchymal stem cells for treatment of osteoarthritis of the metacarpophalangeal/metatarsophalangeal joint in horses: A clinical pilot study.. PLoS One 2019;14(8):e0221317.
- Gugjoo MB, Fazili MR, Gayas MA, Ahmad RA, Dhama K. Animal mesenchymal stem cell research in cartilage regenerative medicine - a review.. Vet Q 2019 Dec;39(1):95-120.
Secure Payments
Satisfaction Guarantee
We offer a 60-day guarantee to ensure you are completely satisfied.
Fast & Free Shipping
We provide fast and free shipping on all orders over $40.